Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO).
The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes. Neither party will have continuing financial obligations to the other. Once termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications.
The investment question is whether greater control over future products can justify the resources needed to develop them.
Ascendis Pharma A/S (NASDAQ:ASND) would regain flexibility over which indications to pursue, how quickly to advance candidates, and whether to seek another partner. Successful independent development could retain more of a product's commercial economics, while a new collaboration could provide another way to share costs and risk.
Monthly dosing offers a clear development objective. If clinical studies demonstrate effective treatment with acceptable tolerability, fewer injections could make long-term therapy more convenient. That potential benefit would matter most if it helps patients stay on treatment without sacrificing outcomes.
#ascendis #pharma #asnd #regain
The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes. Neither party will have continuing financial obligations to the other. Once termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications.
The investment question is whether greater control over future products can justify the resources needed to develop them.
Ascendis Pharma A/S (NASDAQ:ASND) would regain flexibility over which indications to pursue, how quickly to advance candidates, and whether to seek another partner. Successful independent development could retain more of a product's commercial economics, while a new collaboration could provide another way to share costs and risk.
Monthly dosing offers a clear development objective. If clinical studies demonstrate effective treatment with acceptable tolerability, fewer injections could make long-term therapy more convenient. That potential benefit would matter most if it helps patients stay on treatment without sacrificing outcomes.
#ascendis #pharma #asnd #regain
2 months ago
